{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T17:50:56Z","timestamp":1764784256907,"version":"3.44.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ahj.2019.07.014","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T20:30:06Z","timestamp":1564086606000},"page":"42-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Use and 1-year outcomes with conventional and drug-coated balloon angioplasty in patients with lower extremity peripheral artery disease"],"prefix":"10.1016","volume":"217","author":[{"given":"Chandler A.","family":"Long","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Zepel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa A.","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley G.","family":"Hammill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manesh R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Schuyler","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.ahj.2019.07.014_bb0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejvs.2006.09.024","article-title":"Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)","volume":"33","author":"Norgren","year":"2007","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"1","key":"10.1016\/j.ahj.2019.07.014_bb0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ecl.2013.09.003","article-title":"Peripheral arterial disease","volume":"43","author":"Mascarenhas","year":"2014","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"9","key":"10.1016\/j.ahj.2019.07.014_bb0015","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","article-title":"Epidemiology of peripheral artery disease","volume":"116","author":"Criqui","year":"2015","journal-title":"Circ Res"},{"issue":"12","key":"10.1016\/j.ahj.2019.07.014_bb0020","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/01.CIR.0000029746.10018.36","article-title":"Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results","volume":"106","author":"Duda","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ahj.2019.07.014_bb0025","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.RVI.0000151260.74519.CA","article-title":"Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial","volume":"16","author":"Duda","year":"2005","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"10.1016\/j.ahj.2019.07.014_bb0030","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1583\/05-1704.1","article-title":"Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial","volume":"13","author":"Duda","year":"2006","journal-title":"J Endovasc Ther"},{"issue":"7","key":"10.1016\/j.ahj.2019.07.014_bb0035","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa0706356","article-title":"Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg","volume":"358","author":"Tepe","year":"2008","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ahj.2019.07.014_bb0040","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1161\/CIRCULATIONAHA.107.735985","article-title":"Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial","volume":"118","author":"Werk","year":"2008","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ahj.2019.07.014_bb0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1161\/CIRCINTERVENTIONS.111.962324","article-title":"Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results","volume":"4","author":"Dake","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"issue":"5","key":"10.1016\/j.ahj.2019.07.014_bb0050","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1583\/11-3560.1","article-title":"Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study","volume":"18","author":"Dake","year":"2011","journal-title":"J Endovasc Ther"},{"issue":"6","key":"10.1016\/j.ahj.2019.07.014_bb0055","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/CIRCINTERVENTIONS.112.971630","article-title":"Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial","volume":"5","author":"Werk","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2019.07.014_bb0060","doi-asserted-by":"crossref","unstructured":"Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 2013. 61(24):2417\u20132427.","DOI":"10.1016\/j.jacc.2013.03.034"},{"issue":"1","key":"10.1016\/j.ahj.2019.07.014_bb0065","first-page":"10","article-title":"The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization","volume":"7","author":"Scheinert","year":"2014","journal-title":"first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty JACC Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.ahj.2019.07.014_bb0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1406235","article-title":"Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease","volume":"373","author":"Rosenfield","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ahj.2019.07.014_bb0075","first-page":"495","article-title":"Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN","volume":"131","author":"Tepe","year":"2015","journal-title":"PACT SFA randomized trial Circulation"},{"key":"10.1016\/j.ahj.2019.07.014_bb0080","doi-asserted-by":"crossref","unstructured":"Tepe G, Schnorr B, Albrecht T, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv 2015. 8(1 Pt A):102\u20138.","DOI":"10.1016\/j.jcin.2014.07.023"},{"key":"10.1016\/j.ahj.2019.07.014_bb0085","doi-asserted-by":"crossref","unstructured":"Kayssi A, Al-Atassi T, Oreopoulos G, Roche-Nagle G, Tan KT, Rajan DK. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. Cochrane Database Syst Rev 2016(8): CD011319.","DOI":"10.1002\/14651858.CD011319.pub2"},{"issue":"12","key":"10.1016\/j.ahj.2019.07.014_bb0090","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/CIRCULATIONAHA.117.028893","article-title":"Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies","volume":"136","author":"Krishnan","year":"2017","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ahj.2019.07.014_bb0095","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcin.2013.01.128","article-title":"2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease","volume":"6","author":"Micari","year":"2013","journal-title":"evidence from a multicenter registry JACC Cardiovasc Interv"},{"issue":"24","key":"10.1016\/j.ahj.2019.07.014_bb0100","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011245","article-title":"Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"7","author":"Katsanos","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.ahj.2019.07.014_bb0105","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/01.mlr.0000160417.39497.a9","article-title":"Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors","volume":"43","author":"Birman-Deych","year":"2005","journal-title":"Med Care"},{"issue":"11","key":"10.1016\/j.ahj.2019.07.014_bb0110","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"5","key":"10.1016\/j.ahj.2019.07.014_bb0115","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"10 Supl 2","key":"10.1016\/j.ahj.2019.07.014_bb0120","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1097\/MLR.0b013e31806518ac","article-title":"Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases","volume":"45","author":"Curtis","year":"2007","journal-title":"Med Care"},{"issue":"19","key":"10.1016\/j.ahj.2019.07.014_bb0125","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1002\/sim.2813","article-title":"A comparison of the statistical power of different methods for the analysis of cluster randomization trials with binary outcomes","volume":"26","author":"Austin","year":"2007","journal-title":"Stat Med"},{"issue":"11","key":"10.1016\/j.ahj.2019.07.014_bb0130","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jcin.2017.03.033","article-title":"The Effect of Clinical Care Location on Clinical Outcomes After Peripheral Vascular Intervention in Medicare Beneficiaries","volume":"10","author":"Turley","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.ahj.2019.07.014_bb0135","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/jamacardio.2019.0325","article-title":"Association of Survival with Femoropopliteal Artery Revascularization with Drug-Coated Device","volume":"4","author":"Secemsky","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"21","key":"10.1016\/j.ahj.2019.07.014_bb0140","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.jacc.2015.09.063","article-title":"Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA","volume":"66","author":"Laird","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2019.07.014_bb0145","first-page":"497","article-title":"Stellarex drug-coated balloon for treatment of femoropopliteal arterial disease-The ILLUMENATE Global Study: 12-Month results from a prospective, multicenter, single-arm study","volume":"91","author":"Schroe","year":"2018","journal-title":"Catheter Cardiovasc Interv"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319301899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870319301899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:02:32Z","timestamp":1757570552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870319301899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":29,"alternative-id":["S0002870319301899"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2019.07.014","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use and 1-year outcomes with conventional and drug-coated balloon angioplasty in patients with lower extremity peripheral artery disease","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2019.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}